OR WAIT null SECS
Adaptimmune entered into a manufacturing agreement with PCT for the manufacture of its SPEAR T-cell therapies.
On Sept. 19, 2016, Adaptimmune announced that it has entered into a strategic manufacturing agreement with PCT, a subsidiary of Caladrius Biosciences, for the supply of Adaptimmune’s SPEAR T-cell therapies. Under the terms of the agreement, Adaptimmume will benefit from exclusive access to an EU- and FDA-compliant manufacturing unit at PCT, the company said in a press announcement.
SPEAR T-cell therapies are novel cancer immunotherapies that use affinity T-cell receptors (TCR) to target and destroy cancer cells by strengthening patient’s natural T-cell response. Adaptimmune’s SPEAR T-cells are manufactured by isolating T-cells from the blood of cancer patients, transferring affinity enhanced TCRs, which have been modified to recognized cancer cells, into the cells; activating and expanding the T-cells; and, introducing the affinity enhanced cells back into the patient to enable the patient's immune system to attack cancer.